|
|
 |
Media Release:
(September 25, 2007)
It would appear that the natural health industry has
embraced a new era in personal health as it enters the market of nutraceutical supplements. The
term nutraceutical is a portmanteau of "nutrition" and "pharmaceutical" and
refers to foods claimed to have a medicinal effect on human health. Such foods
are also called functional foods and can also refer to individual chemicals
present in common foods.
Recently it was announced by ReGen Therapeutics that
it had entered into an exclusive license agreement with Metagenics Inc for the
commercialization of ReGen's proline-rich polypeptide complex (PRP),
Colostrinin™, as a nutraceutical for humans in North America & Australia (the 'Agreement').
Metagenics will market Colostrinin™ as the active ingredient in its healthy brain
aging support formula, CogniSure™ in Northern America & Colostrinin™ in
Australia.
The Agreement is conditional on, among other things, the satisfactory completion of
toxicology testing on Colostrinin and of due diligence by Metagenics on the
Colostrinin™ manufacturing facilities in South Dakota. Subject to satisfactory
completion of the conditions of the Agreement and requisite U.S. regulatory
filings, it is anticipated launch of CogniSure™ & Colostrinin™ by the end of
2007.
ReGen Therapeutics is a UK listed Biotech company which is developing three
business lines—human and veterinary nutraceuticals, prescription pharmaceuticals
for the treatment of neurodegenerative diseases, and a clinical research
organization, which oversees Phase I and Phase II both for ReGen and external
customers.
ReGen's business strategy is to develop its nutraceutical and
pharmaceutical products to a state where they can be licensed out and marketed
by a third party. Its only direct sales are currently through its clinical
research organization, www.regentherapeutics.com. ReGen's shares are traded on
the AIM Market of the London Stock Exchange plc (RGT) and are quoted on the Pink
Sheets of the United States over-the-counter market in the form of American
Depositary Receipts.
|
